Literature DB >> 28466120

Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Fatima A Ballout1, Ahmad S Manshad1, Tochukwu M Okwuosa2.   

Abstract

OPINION STATEMENT: Pulmonary hypertension is caused by cancer and its therapeutic agents including chemotherapy, radiotherapy, and even the targeted therapies. Ironically, some of the cancer therapies that cause one type of pulmonary hypertension (PH) could potentially be employed in the treatment of another PH type. Greater awareness on the role of cancer therapeutic agents in causing PH is required. Conversely, since PH is mostly incurable, the potential role of some of these cancer therapeutic agents in the cure of PH should be recognized. In short, the relationship between cancer, cancer therapy, and PH is an interesting one requiring further attention, education, and research.

Entities:  

Keywords:  Cardio-oncology; Pulmonary hypertension; Pulmonary hypertension diagnosis

Year:  2017        PMID: 28466120     DOI: 10.1007/s11936-017-0543-5

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  96 in total

1.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2016-02

Review 2.  Chronic thromboembolic pulmonary hypertension.

Authors:  Marius M Hoeper; Eckhard Mayer; Gérald Simonneau; Lewis J Rubin
Journal:  Circulation       Date:  2006-04-25       Impact factor: 29.690

Review 3.  Chemotherapy-induced pulmonary hypertension: role of alkylating agents.

Authors:  Benoît Ranchoux; Sven Günther; Rozenn Quarck; Marie-Camille Chaumais; Peter Dorfmüller; Fabrice Antigny; Sébastien J Dumas; Nicolas Raymond; Edmund Lau; Laurent Savale; Xavier Jaïs; Olivier Sitbon; Gérald Simonneau; Kurt Stenmark; Sylvia Cohen-Kaminsky; Marc Humbert; David Montani; Frédéric Perros
Journal:  Am J Pathol       Date:  2014-12-11       Impact factor: 4.307

4.  Point mutations in human GLI3 cause Greig syndrome.

Authors:  A Wild; M Kalff-Suske; A Vortkamp; D Bornholdt; R König; K H Grzeschik
Journal:  Hum Mol Genet       Date:  1997-10       Impact factor: 6.150

5.  Pulmonary intravascular lymphomatosis: presentation with dyspnea and air trapping.

Authors:  J G Walls; Y G Hong; J E Cox; K M McCabe; K E O'Brien; J P Allerton; S Derdak
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

6.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

7.  Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension.

Authors:  L S Snyder; K R Harmon; R D Estensen
Journal:  Chest       Date:  1989-11       Impact factor: 9.410

8.  Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?

Authors:  Douglas R Stewart; Joy D Cogan; Mordechai R Kramer; Wallace T Miller; Leif E Christiansen; Michael W Pauciulo; Ludwine M Messiaen; George S Tu; William H Thompson; Reed E Pyeritz; Jay H Ryu; William C Nichols; Makoto Kodama; Barbara O Meyrick; David J Ross
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

9.  Role of Src tyrosine kinases in experimental pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Eva Maria Berghausen; Swati Dabral; Aleksandra Tretyn; Elsa Butrous; Rajkumar Savai; Ghazwan Butrous; Bhola Kumar Dahal; Ralf P Brandes; Hossein Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Stephan Rosenkranz; Ralph Theo Schermuly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-19       Impact factor: 8.311

10.  Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

Authors:  F J Giles; M J Mauro; F Hong; C-E Ortmann; C McNeill; R C Woodman; A Hochhaus; P D le Coutre; G Saglio
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528

View more
  4 in total

Review 1.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

Authors:  Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

2.  Pulmonary hypertension is associated with an increased incidence of cancer diagnoses.

Authors:  Christoph Roderburg; Sven H Loosen; Hans-Joerg Hippe; Tom Luedde; Karel Kostev; Mark Luedde
Journal:  Pulm Circ       Date:  2022-04-01       Impact factor: 2.886

3.  A case of severe cancer-related pulmonary hypertension; An unexpected resolution.

Authors:  Isam Albaba; Boris I Medarov
Journal:  Respir Med Case Rep       Date:  2022-05-23

4.  Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data.

Authors:  Xiao-Min Mu; Wei Wang; Fang-Yi Wu; Yu-Ying Jiang; Ling-Ling Ma; Jia Feng
Journal:  Int J Environ Res Public Health       Date:  2020-10-31       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.